Lacidipine

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Lacidipine
Lacidipine structure.svg
Clinical data
Trade namesLacipil, Motens
AHFS/Drugs.comInternational Drug Names
Routes of
administration
Oral
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability~10%
Protein binding>95%
MetabolismHepatic
Onset of action30–50 min
Elimination half-life13–19 hours
ExcretionFeces (~70%)
Identifiers
  • Diethyl 4-{o-[(E)-2-tert-butoxycarbonylethenyl]phenyl}-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
ECHA InfoCard100.166.373 Edit this at Wikidata
Chemical and physical data
FormulaC26H33NO6
Molar mass455.551 g·mol−1
3D model (JSmol)
  • CCOC(=O)C1=C(NC(=C(C1C2=CC=CC=C2/C=C/C(=O)OC(C)(C)C)C(=O)OCC)C)C
  • InChI=1S/C26H33NO6/c1-8-31-24(29)21-16(3)27-17(4)22(25(30)32-9-2)23(21)19-13-11-10-12-18(19)14-15-20(28)33-26(5,6)7/h10-15,23,27H,8-9H2,1-7H3/b15-14+
  • Key:GKQPCPXONLDCMU-CCEZHUSRSA-N
  (verify)

Lacidipine (tradenames Lacipil or Motens) is a calcium channel blocker. It is available as tablets containing 2 or 4 mg.

It was patented in 1984 and approved for medical use in 1991.[1]

References[edit]

  1. ^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 466. ISBN 9783527607495.

External links[edit]